1. Diabetic Microvascular Disease: The Role of Glycemic Control and the Impact on Public Health Robert E. Ratner, MD MedStar Research Institute Georgetown University Medical School Washington, DC

2. Diabetes: The Numbers The National Diabetes Education Program www.ndep.nih.gov A joint program of NIH and CDC December 2006 EVERY 24 HOURS New Cases – 4,100 Amputations – 230 (60% of non-traumatic amputations annually) Blindness – 55 (#1 cause) Kidney Failure – 120 (#1 cause) Derived from NIDDK, National Diabetes Statistics fact sheet. HHS, NIH, 2005.

3. Adjusted ESRD incident rates of ESRD due to diabetes lla illi lla illi Incident ESRD patients; adjusted for age, gender, & race. USRDS, accessed July 13, 2007

4. Prevalence of Visual Impairment per 100 Adults with Diabetes, by Age, United States, 1997–2003 Source: National Diabetes Surveillance System – CDC website (http://www.cdc.gov/diabetes/statistics/index.htm)

5. What Complications do People with Diabetes Get? Ramsey SD. Pharmacoeconomics 3:285, 1999

6. Cumulative Incidence of Proliferative Retinopathy: The Pittsburgh EDC Study Pambianco G. Diabetes 55:1463, 2006 Diagnosed between 1965-1969 1970-1974 1975-1980 %

7. Cumulative Incidence of Overt Nephropathy: The Pittsburgh EDC Study Pambianco G. Diabetes 55:1463, 2006 Diagnosed between 1965-1969 1970-1974 1975-1980 %

8. Cumulative Incidence of Autonomic Neuropathy: The Pittsburgh EDC Study Pambianco G. Diabetes 55:1463, 2006 Diagnosed between 1965-1969 1970-1974 1975-1980 %

9. Cumulative Incidence of Peripheral Neuropathy: The Pittsburgh EDC Study % Diagnosed between 1965-1969 1970-1974 1975-1980 Pambianco G. Diabetes 55:1463, 2006

10. Cumulative Incidence of Hard End-Points: The Pittsburgh EDC Study Renal Failure Total CAD Pambianco G. Diabetes 55:1463, 2006 % % %

11. Metabolic Pathways Leading to Microvascular Complications Brownlee M. Diabetes 54:1615, 2005

12. Metabolic Pathways Leading to Microvascular Complications Brownlee M. Diabetes 54:1615, 2005

13. Metabolic Pathways Leading to Microvascular Complications Brownlee M. Diabetes 54:1615, 2005

14. Prevalence of Retinopathy: The AusDiab Study Tapp RJ. Diabetes Res Clin Pract 73:315, 2006

15. Prevalence of Microalbuminuria: The AusDiab Study Tapp RJ. Diabetes Res Clin Pract 73:315, 2006

16. DCCT: Relationship between Glycemic Control and Retinopathy Progression Lachin J. Diabetes 57:995, 2008

17. DCCT: Microvascular Complications and Glycemic Control Lachin J. Diabetes 57:995, 2008

18. Microvascular Endpoints (cumulative) renal failure or death, vitreous haemorrhage or photocoagulation 346 of 3867 patients (9%)

19. Aggregate Clinical Endpoints

20. Glucose Control Study Summary The intensive glucose control policy maintained a lower HbA 1c by mean 0.9 % over a median follow up of 10 years from diagnosis of type 2 diabetes with reduction in risk of: 12%for any diabetes related endpoint p=0.029 25%for microvascular endpoints p=0.0099 21%for retinopathy at twelve years p=0.015 33%for albuminuria at twelve years p=0.000054

21. Microvascular Endpoints 0.5 1 10 15 0567891011 37% decrease per 1% decrement in HbA1c p<0.0001 Updated mean HbA 1c Hazard ratio UKPDS 35. BMJ 2000; 321: 405-12

22. Steno 2: Long-term Outcomes of Intensive Management Gaede P. NEJM 358:580, 2008

23. Steno 2: Long-term Outcomes of Intensive Management Gaede P. NEJM 358:580, 2008

24. Steno 2: Long-term Outcomes of Intensive Management Gaede P. NEJM 358:580, 2008

25. Steno 2: Long-term Outcomes of Intensive Management Gaede P. NEJM 358:580, 2008

32. UKPDS: A1c as Predictor of Micro- and Macrovascular Disease Microvascular Myocardial infarction - 1 2 3 4 5 6 7 8 9 10 56789 11 Updated Mean A1c Est. Hazard Ratio Stratton IM et al. BMJ. 2000; 321:405-412.

33. Temporal Changes in Glycemic Control: NHANES Hoerger TJ. Diabetes Care 31:81, 2008

34. Age-adjusted Mortality, age 35-74 years NHANES Gregg EW. Ann Int Med 147:149, 2007

35. Age-adjusted Mortality, age 35-74 years NHANES Gregg EW. Ann Int Med 147:149, 2007

36. VADT: Correlation of Retinopathy with Coronary Calcium Scores Reaven P. Diabetes Care 31:952, 2008